Table 3.
Antiproliferative activity of compounds 6, 7, 9 and 10 on five human cancer cell lines and non-tumorigenic line Balb/3T3 given as IC50 ± SD (µM), with cisplatin (CDDP) used as reference.
| Cpd. | MCF-7 | MDA-MB-231 | A-549 | LoVo | LoVoDX | Balb/3T3 |
|---|---|---|---|---|---|---|
| 6b | 31.8 ± 7.8 | 35.0 ± 10.0 | 27.2 ± 7.7 | 32.4 ± 2.6 | [a] | 38.4 ± 3.5 |
| 6c | 5.3 ± 0.9 | 5.0 ± 0.8 | 6.2 ± 1.4 | 8.7 ± 1.1 | 6.4 ± 0.4 | 5.3 ± 1.2 |
| 6d | 4.5 ± 0.5 | 6.1 ± 0.6 | 5.6 ± 0.9 | 6.7 ± 0.7 | 6.2 ± 0.6 | 5.8 ± 0.9 |
| 7a | 74.5 ± 5.8 | 53.3 ± 5.5 | 60.7 ± 12.1 | 75.8 ± 6.5 | [a] | 19.7 ± 1.9 |
| 7b | 15.5 ± 2.5 | 15.2 ± 4.4 | 12.0 ± 4.0 | 16.4 ± 1.7 | 23.0 ± 2.2 | 7.6 ± 0.9 |
| 7c | 4.5 ± 0.4 | 7.1 ± 0.8 | 4.0 ± 1.1 | 6.3 ± 0.5 | 4.5 ± 0.4 | 5.3 ± 0.4 |
| 7d | 6.8 ± 0.5 | 10.8 ± 0.4 | 6.6 ± 1.4 | 9.6 ± 0.9 | 8.6 ± 0.9 | 3.1 ± 0.6 |
| 7e | 100.8 ± 11.3 | 74.5 ± 7.7 | [a] | 81.7 ± 12.4 | [a] | [a] |
| 9d | [a] | 56.0 ± 7.1 | 33.4 ± 6.4 | [b] | [b] | [b] |
| 10d | 22.0 ± 4.5 | 24.4 ± 3.0 | 14.0 ± 5.6 | 70.3 ± 21.5 | 33.1 ± 9.0 | 42.2 ± 9.3 |
| CDDP | 6.0 ± 2.2 | 24.4 ± 4.8 | 2.7 ± 1.0 | 4.4 ± 0.3 | 3.4 ± 0.2 | 10.2 ± 4.8 |
[a] IC50 exceeds highest concentration used (100µM), [b] not tested.